HyperMed Imaging, Inc. is the established leader in medical hyperspectral imaging for surface tissue oximetry. HyperMed's pioneering technology has
been in service since 2006 and has been shown in published clinical research to effectively assess oxyhemoglobin, deoxyhemoglobin and
oxyhemoglobin saturation in superficial tissue for a number of key healthcare applications.
HyperMed has developed a new product using the same breakthrough imaging technology as used in HyperMed’s OxyVu™-1 system. HyperMed’s new product, called HyperView™, is FDA 510(k) cleared and CE marked. HyperView is designed to deliver the same diagnostic information in a smaller,
more portable configuration to Primary Care clinics and in secondary care vascular surgery departments.
There are many medical applications requiring a need to quickly and efficiently determine superficial tissue oxygenation. Ischemic tissue leads to complications such as non-healing wounds and surgical intervention. In many cases, there is a need to determine perfusion of oxygenated hemoglobin
as well as adequate blood supply and exchange. Applications include wound care, reconstructive surgery, amputation, and vascular procedures.
Patients in need include those with compromised vascular systems such as those who suffer from diabetes, peripheral vascular disease and
limb ischemia. For these patients, limb preservation and limb salvage is of great importance.
Current standard of care devices for front line vascular diagnostics include Ankle Brachial Index (ABI) and Transcutaneous Partial Pressure of Oxygen (TcPO2). ABI requires contact with the patient and does not assess tissue oxygenation levels. ABI is often misleading or incorrect when applied to the
diabetic lower extremity. TcPO2 does assess surface oxygenation but requires contact and heating of the patient skin. Neither ABI nor TcPO2 can
provide a medical diagnostic image.
Other diagnostic imaging products utilize techniques such as laser doppler or injectable fluorescent agents to assess blood flow. However, these
technologies do not discern oxygenated from deoxygenated hemoglobin and thus, they do not assess the key biomarkers of tissue oxygenation.
HyperMed’s technology utilizes a proprietary form of hyperspectral imaging to assess oximetry in superficial tissue. It does not require contact with the patient
and does not require injectable contrast. It uses visible light and a spectrometer to image and quantify light absorption in hemoglobin molecules. HyperMed’s hyperspectral imaging technology is designed to differentiate light absorption between oxygenated hemoglobin and deoxygenated hemoglobin. The technology
presents the data as color-coded images depicting approximate concentrations of oxyhemoglobin and deoxyhemoglobin, as well as oxygen saturation. Software
tools allow the clinician to analyze various areas within the image corresponding to locations on the skin surface. Such analysis information is useful to
determine the location of ischemic tissue.
Oxy Deoxy O2Sat Visual
The technology presents the data as color-coded images depicting approximate concentrations of oxyhemoglobin and deoxyhemoglobin, as well as
oxygen saturation. Software tools allow the clinician to analyze various areas within the image corresponding to locations on the skin surface.
Such tools are useful to determine the location of ischemic tissue.
HyperMed Imaging’s new product, HyperView™, is a handheld, battery operated, portable diagnostic imaging device that is used to assess tissue
oxygenation without contacting the patient. The product is intended for use by physicians and healthcare professionals as a noninvasive tissue
oxygenation measurement system that reports an approximate value of oxygen saturation (O2Sat), oxyhemoglobin level (Oxy), and deoxyhemoglobin
level (Deoxy) in superficial tissue. The HyperView system displays two-dimensional, color-coded images of tissue oxygenation of the scanned surface.
Images and data provide hyperspectral tissue oxygenation measurements for selected tissue regions. The product is indicated for use to determine oxygenation levels in superficial tissues for patients with potential circulatory compromise.
Our pioneering technology was first commercialized by HyperMed Inc. with a prior product called OxyVu™-1, which was FDA cleared in 2006.
OxyVu-1 is no longer being produced or sold. It was a cart-based mobile imaging system that has been shown in published clinical research to assess oxyhemoglobin, deoxyhemoglobin and oxyhemoglobin saturation in superficial tissue associated with a number of important healthcare applications
including complications associated with vascular compromise, such as wound healing, diabetic foot ulcers, amputation and critical limb ischemia.